MCM
NVAX icon

Mendel Capital Management’s Novavax NVAX Stock Holding History

Mendel Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,860
Closed -$315K – 97
2024
Q2 		$315K Hold
24,860
– – 0.2% 78
2024
Q1 		$119K Hold
24,860
– – 0.08% 95
2023
Q4 		$119K Hold
24,860
– – 0.09% 90
2023
Q3 		$180K Hold
24,860
– – 0.15% 87
2023
Q2 		$185K Hold
24,860
– – 0.15% 90
2023
Q1 		$172K Hold
24,860
– – 0.16% 84
2022
Q4 		$256K Buy
24,860
+1,025
+4% +$18.1K 0.27% 57
2022
Q3 		$434K Hold
23,835
– – 0.51% 39
2022
Q2 		$1.23M Buy
23,835
+10,146
+74% +$526K 1.37% 14
2022
Q1 		$1.01M Buy
13,689
+3,075
+29% +$274K 0.95% 22
2021
Q4 		$1.52M Buy
+10,614
New +$1.82M 1.39% 11

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mendel Capital Management's NVAX Position: Q3 2024 in Review

Mendel Capital Management sold out of Novavax (NVAX) in Q3 2024, closing a stake of 24,860 shares — an estimated $315K sold.

Mendel Capital Management first reported a position in NVAX in Q4 2021 and held it in 11 quarters. The position peaked at $1.52M in Q4 2021. 238 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

  • Mendel Capital Management reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
  • Mendel Capital Management sold 24,860 Novavax shares in Q3 2024, an estimated $315K.
  • Mendel Capital Management first reported a position in Novavax in Q4 2021 and held it in 11 quarters.
  • Mendel Capital Management's Novavax position peaked at $1.52M in Q4 2021.
  • 238 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on Mendel Capital Management's 13F filing for Q3 2024, filed 7 Nov 2024.